ArticleMedical oncology (Northwood, London, England)2026
The circMTCL1/miR-145-5p/BMP3 axis suppresses colorectal cancer cell growth by mediating the MAPK signaling pathway.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Circular RNAs play key roles in colorectal cancer (CRC). Here, we examine the function and underlying mechanism of circMTCL1 in CRC. The expression of circMTCL1 in CRC tissues and cell lines were detected by quantitative real-time PCR (qRT-PCR). The function of circMTCL1 was elucidated through overexpression and knockdown studies. Furthermore, a combination of Fluorescence in situ hybridization (FISH), nuclear-cytoplasmic fractionation, RNA immunoprecipitation (RIP), qRT-PCR, Western blotting, and dual-luciferase reporter assays was employed to elucidate the tumor-suppressive mechanism of circMTCL1 in CRC. circMTCL1 was significantly downregulated in CRC tissues compared to adjacent normal tissues, showing a 17.08-fold decrease (P < 0.001). It functioned as a competing endogenous RNA (ceRNA) by specifically binding to miR-145-5p, thereby modulating the expression of Bone Morphogenetic Protein 3 (BMP3). Overexpression of circMTCL1 markedly inhibited the proliferation, migration, and invasion of CRC cells, resulting in a 3.76-fold decrease in proliferation (P < 0.001), and 1.58-fold and 2.00-fold decreases in migration and invasion, respectively (P < 0.001). Furthermore, circMTCL1 overexpression upregulated BMP3 expression by 1.60-fold (P < 0.001). Further investigation revealed that circMTCL1 regulates tumor progression by suppressing the activation of the MAPK signaling pathway. circMTCL1 acts as a tumor suppressor in CRC. Its mechanism likely involves sponging miR-145-5p to regulate BMP3 expression and modulating the MAPK signaling pathway. These findings provide a new perspective on the pathogenesis of CRC and identify a potential therapeutic target for clinical intervention.
Indexed as
Identifiers
42848091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.